Castle Biosciences, Inc. Common Stock (CSTL)
Castle Biosciences, Inc. is a dermatologic oncology company focused on developing assays that assist in diagnosing, prognosing, and managing skin cancer. The company specializes in providing molecular diagnostic tests aimed at improving clinical decision-making and patient care for various skin cancers, including melanoma and dermatologic conditions. Founded in 2010, Castle Biosciences is committed to advancing personalized medicine through innovative diagnostic technologies.
Company News
Castle Biosciences will release its Q3 2025 financial results on November 3, 2025, after market close, with a conference call and webcast to discuss the results at 4:30 p.m. Eastern time.
The FDA is tightening survival standards in cancer research, with private investments helping to fill public funding gaps. Several biotech companies are advancing innovative immunotherapies, with Oncolytics Biotech showing promising results in pancreatic cancer treatment.
The article discusses 5 top small-cap stocks that are Zacks Rank #1 (Strong Buy) or #2 (Buy) stocks, including Soundhound AI, Afya, Castle Biosciences, TriMas, and Immersion. The article provides an overview of each company's business, market cap, stock performance, and earnings growth outlook.
Investors should consider this list of healthcare stocks for 2024
The genetic-testing company beat expectations with its Q2 results.